BIOMERIEUX SA

BIOMERIEUX SA specializes in the design, development, and manufacturing of in vitro diagnostic systems and reagents for clinical microbiology, immunodiagnostics, and molecular testing. The company provides automated platforms and consumables used in hospital and reference laboratories to detect infectious diseases, pathogens, and biomarkers with high precision and throughput. Their technical expertise includes nucleic acid amplification technologies, immunoassay platforms, sample preparation workflows, and integrated laboratory information systems that support regulatory compliance and workflow automation in clinical settings. A key differentiator is their focus on end-to-end diagnostic solutions that combine instrumentation, software, and proprietary reagents to enhance diagnostic accuracy and operational efficiency in high-volume testing environments. Award history is not available to confirm specific agency engagements or contract performance. Consequently, no definitive patterns can be identified regarding federal agency relationships or the nature of government-supported projects. The primary NAICS code 325413 reflects manufacturing of medical diagnostic reagents and related products. In practice, this means the company operates at the intersection of biotechnology and clinical laboratory science, producing certified diagnostic kits and systems that meet CLIA, ISO 13485, and CE-IVDR standards. Their market positioning centers on high-complexity diagnostic manufacturing for healthcare providers requiring validated, reproducible testing platforms. BIOMERIEUX SA is a global entity headquartered in Marcy-l’Étoile, France, with a corporate structure classified as ZZ, indicating no specific U.S. small business certification. The company maintains international manufacturing and distribution networks but has no publicly verifiable U.S. government certifications or registrations tied to its federal contracting activity. Its government market presence cannot be assessed from available award data.